Search Results - "Faroux, R"

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study by Pagès, F, André, T, Taieb, J, Vernerey, D, Henriques, J, Borg, C, Marliot, F, Ben Jannet, R, Louvet, C, Mineur, L, Bennouna, J, Desrame, J, Faroux, R, Kirilovsky, A, Duval, A, Laurent-Puig, P, Svrcek, M, Hermitte, F, Catteau, A, Galon, J, Emile, J-F

“…The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients, was evaluated in the International Duration Evaluation of…”
Get full text

Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial by Louvet, C, Labianca, R, Hammel, P, Lledo, G, Zampino, M G, André, T, Zaniboni, A, Ducreux, M, Aitini, E, Taïeb, J, Faroux, R, Lepere, C, de Gramont, A

“…Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx)…”
Get full text

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results by Aparicio, T., Bouché, O., Taieb, J., Maillard, E., Kirscher, S., Etienne, P.-L., Faroux, R., Khemissa Akouz, F., El Hajbi, F., Locher, C., Rinaldi, Y., Lecomte, T., Lavau-Denes, S., Baconnier, M., Oden-Gangloff, A., Genet, D., Paillaud, E., Retornaz, F., François, E., Bedenne, L.

“…Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy (CT) is a standard treatment but…”
Get full text

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer by Mineur, L, François, E, Plassot, C, Phelip, J M, Miglianico, L, Dourthe, L M, Bonichon, N, Moreau, L, Guimbaud, R, Smith, D, Achille, E, Hervé, R, Bons, J M, Remy, S, Faroux, R, Villing, A L, Mahamat, A, Rabbia, I, Soulié, P, Baumgaertner, I, Mathé, N, Vazquez, L, Boustany, R

“…Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data…”
Get full text

Corrigendum to ‘Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study’: Annals of Oncology 2020; Volume 31: 921-929 by Pagès, F., André, T., Taieb, J., Vernerey, D., Henriques, J., Borg, C., Marliot, F., Ben Jannet, R., Louvet, C., Mineur, L., Bennouna, J., Desrame, J., Faroux, R., Kirilovsky, A., Duval, A., Laurent-Puig, P., Svrcek, M., Hermitte, F., Catteau, A., Galon, J., Emile, J-F.

Get full text

Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study by Nahon, S, Hagège, H, Latrive, J P, Rosa, I, Nalet, B, Bour, B, Faroux, R, Gower, P, Arpurt, J P, Denis, J, Henrion, J, Rémy, A J, Pariente, A

“…The mortality rate from upper gastrointestinal bleeding (UGIB) remains high, at 5 % - 10 %. The aim of the current study was to describe the epidemiological…”
Get more information

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results by Aparicio, T, Bouché, O, Taieb, J, Maillard, E, Kirscher, S, Etienne, P -L, Faroux, R, Khemissa Akouz, F, El Hajbi, F, Locher, C, Rinaldi, Y, Lecomte, T, Lavau-Denes, S, Baconnier, M, Oden-Gangloff, A, Genet, D, Paillaud, E, Retornaz, F, François, E, Bedenne, L

Get full text

Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method by Boisdron-Celle, M., Metges, J., Capitain, O., Faroux, R., Stampfli, C., Ferec, M., Laplaige, P., Lecomte, T., Matysiak-Budnik, T., Senellart, H., Campone, M., Morel, A., Gamelin, E.

Get full text

Postoperative irinotecan in resected stage II–III rectal cancer: final analysis of the French R98 Intergroup trial by Delbaldo, C., Ychou, M., Zawadi, A., Douillard, J.Y., André, T., Guerin-Meyer, V., Rougier, P., Dupuis, O., Faroux, R., Jouhaud, A., Quinaux, E., Buyse, M., Piedbois, P.

“…The R98 trial explores the addition of irinotecan to a 5-fluorouracil (5-FU) plus leucovorin (5-FU/LV) adjuvant regimen in optimally resected stages II–III…”
Get full text

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial by Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., Taieb, J., Brucker, P., Landi, B., Flesch, M., Carola, E., Martin, P., Vaillant, E., de Gramont, A.

“…The sequential FOLFOX7–FOLFIRI combination is not superior to FOLFOX4 in colorectal cancer patients with resectable metastases. Patients with synchronous…”
Get full text

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer by Conroy, T, Hebbar, M, Bennouna, J, Ducreux, M, Ychou, M, Llédo, G, Adenis, A, Faroux, R, Rebischung, C, Kockler, L, Douillard, J Y

“…Background: A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6)…”
Get full text

P-136Evolution of efficacy and safety of cetuximab with the determination of RAS status in Metastatic Colorectal Cancer (mCRC) elderly patients by Metges, J-P, Capitain, O, Ramee Jean, F, Raoul Jean, L, Douillard, J-Y, Etienne Pierre, L, Cumin, I, Dupuis, O, Faroux, R, Coulon, M-A, Deguiral, P, Le Rol, A, Achour Nacr, E, Gorlaouen, A, Bouret, J-F, Marhuenda, F, Deniel Lagadec, D, Grude, F

Get full text

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial by Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., de Gramont, A.

Get full text

688 RISK FACTORS FOR HEPATOCELLULAR CARCINOMA OR LIVER FAILURE IN CAUCASIANS PATIENTS WITH NON-VIRAL CIRRHOSIS: THE IMPORTANCE OF PAST OVERWEIGHT by Archambeaud, I, Auble, H, Fallot, G, Scoul, C, Bardot, S, Roche, B, Faroux, R, Samuel, D, Nahon, P, Feray, C

Get full text

Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6 by Perrocheau, G, Bennouna, J, Ducreux, M, Hebbar, M, Ychou, M, Lledo, G, Conroy, T, Dominguez, S, Faroux, R, Florentin, V, Douillard, J Y

“…In a recent randomized study, we demonstrated that XELOX (oxaliplatin + oral capecitabine) was well tolerated and not inferior in terms of efficacy to the…”
Get more information

648 TREATMENT OF HEPATOCELLULAR CARCINOMA WITH SORAFENIB: RESULTS IN THE REAL LIFE OF CHANGH COHORT by Rosa, I, Denis, J, Dobrin, A.S, Becker, C, Faroux, R, Bader, R, Danne, O, Causse, X, Diaz, E, Le Dréau, G, Condat, B, Marks, B, Henrion, J, Zerouala, F, Decaens, T, Lesgourgues, B, Bellaiche, G, Labadie, H, Pauwells, A, Renard, P, Hagège, H

Get full text

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer by DELORD, J.-P, BENNOUNA, J, NAMAN, H, DOUILLARD, J. Y, BUGAT, R, ARTRU, P, PERRIER, H, HUSSEINI, F, DESSEIGNE, F, FRANCOIS, E, FAROUX, R, SMITH, D, PIEDBOIS, P

“…This phase II trial was performed to evaluate the efficacy and tolerability of oral tegafur-uracil (UFT) with leucovorin (LV) combined with intravenous (i.v.)…”
Get full text

585 A FRENCH MULTICENTRIC LONGITUDINAL DESCRIPTIVE STUDY OF HEPATOCELLULAR CARCINOMA MANAGEMENT (THE CHANGH COHORT): PRELIMINARY RESULTS by Rosa, I, Denis, J, Renard, P, Lesgourgues, B, Dobrin, A.S, Becker, C, Faroux, R, Causse, X, Diaz, E, Le Dréau, G, Marks, B, Henrion, J, Zerouala, F, Decaens, T, Baderr, R, Danne, O, Rémy, A.J, Nalet, B, Morin, T, Renou, C, Ha gège, H

Get full text

Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas ( Observatoire dédié au Cancer Bretagne / Pays de la Loire ) by Metges, J P, Lebot, M A, Faroux, R, Riaud, F, Gamelin, E, Capitain, O, Guérin Meyer, V, Leynia, P, Douillard, J Y, Senellart, H, Rochard, S, Louvigné, C, Campion, L, Dupuis, O, Grollier, C, Achour, N A, Person, B, Raoul, J L, Boucher, E, Bertrand, C, Ramée, J F, Guivarch, L, Etienne, P L, Roussel, S, Desclos, H, Julien, M N, Labarre, M I, Klein, V, Bessard, R, Stampfli, C, Royet, F, Faycal, J, Gouva, S, Le Bihan, G, Couturier, M, Gourlaouen, A, Bertholom, C, Porneuf, M, Jobard, E, Peguet, E, Grasset, D, Bouret, J F, Bicheler, V, Ulvoas, A, Miglianico, L, Chouzenoux, C, Deguiral, P, Derenne, L, Martin, D, Langlet, P Michel, Bodin, C, Rossi, V, Barré, S, Cojocarasu, O, Naveau Ploux, C, Vidal, A M, Cumin, I, Egreteau, J, Brouard, A, Matysiak Budnik, T, Thomaré, P, Le Bris Michel, A S, Piriou, G, Largeau, R, Elhannani, C, Crespeau, E, Suberville, F, Bourgeois, H, Riche, C, Lagadec, D Déniel, Marhuenda, F, Grudé, F

“…In 2006, bevacizumab, a targeted therapy agent was combined with FOLFIRI for the firstline treatment of patients with unresectable metastatic colorectal…”
Get full text

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study by Phelip, Jean Marc, Desrame, Jérôme, Edeline, Julien, Barbier, Emilie, Terrebonne, Eric, Michel, Pierre, Perrier, Hervé, Dahan, Laetitia, Bourgeois, Vincent, Akouz, Faiza Khemissa, Soularue, Emilie, Ly, Valérie Lebrun, Molin, Yann, Lecomte, Thierry, Ghiringhelli, François, Coriat, Romain, Louafi, Samy, Neuzillet, Cindy, Manfredi, Sylvain, Malka, David

“…Whether triplet chemotherapy is superior to doublet chemotherapy in advanced biliary tract cancer (BTC) is unknown. In this open-label, randomized phase II-III…”
Get full text